Headlines about BioTelemetry (NASDAQ:BEAT) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. BioTelemetry earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 46.4768351847959 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
BEAT has been the topic of several recent analyst reports. Raymond James Financial initiated coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 target price on the stock. BidaskClub upgraded shares of BioTelemetry from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Dougherty & Co restated a “buy” rating and set a $40.00 price objective on shares of BioTelemetry in a report on Wednesday, November 8th. SunTrust Banks initiated coverage on shares of BioTelemetry in a report on Monday, October 23rd. They set a “buy” rating and a $41.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $42.86.
BioTelemetry (BEAT) traded up $1.10 during midday trading on Thursday, reaching $31.60. 477,408 shares of the company were exchanged, compared to its average volume of 454,939. The company has a market capitalization of $988.45, a PE ratio of 24.12, a P/E/G ratio of 1.40 and a beta of 0.53. BioTelemetry has a twelve month low of $21.05 and a twelve month high of $39.20. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60.
BioTelemetry (NASDAQ:BEAT) last announced its earnings results on Tuesday, November 7th. The medical research company reported $0.16 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.25 by ($0.09). BioTelemetry had a return on equity of 13.66% and a net margin of 16.10%. The company had revenue of $81.02 million for the quarter, compared to analyst estimates of $82.10 million. During the same quarter in the previous year, the company posted $0.21 earnings per share. BioTelemetry’s revenue for the quarter was up 52.7% on a year-over-year basis. equities analysts predict that BioTelemetry will post 0.83 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/11/biotelemetry-beat-earns-news-sentiment-score-of-0-20.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.